We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips (PHG) Extends Isala Partnership, Boosts Customer Base
Read MoreHide Full Article
Philips (PHG - Free Report) recently announced the renewal of its long-standing partnership with Isala hospital in a bid to enhance healthcare delivery through innovative, cost-effective solutions.
Per the terms, Isala hospital will use Philips' technology to optimize healthcare processes and deliver patient-centered, accessible, affordable, and cost-effective care.
The hospital will also replace medical systems like MRI and CT scanners with Philips' essential imaging systems and support services, ensuring continuous updates and sustainability.
The latest partnership has added strength to Philips’ customer base.
Philips’ shares have gained 26.4% in the year-to-date period, outperforming the industry’s growth of 6.2%. The company is benefiting from a strengthening clientele on the back of its strong portfolio.
Philips entered into a 10-year strategic collaboration with Nicklaus Children's Health System. Nicklaus will use Philips technologies like Ingenia Ambition X MR and EPIQ CVx ultrasound, AI-enabled radiology workflow solutions, and patient experience technologies to improve patient and staff experience, outcomes, and innovation in pediatric care.
Philips expanded its clientele with the Bon Secours Mercy Health (BSMH) partnership. Per the terms, BSMH will utilize Philips’ scalable patient monitoring platform, standardizing data integration for 49 hospitals, reducing costs and enabling reinvestment in innovation.
Moreover, 14 major hospitals across Madrid, Barcelona, Bilbao, Alicante, Madrid, Cadiz, and Navarra are using Philips’ ambulatory cardiac monitoring service to detect post-discharge Atrial Fibrillation (AF), monitor patients for AF after cardiac ablation or heart valve replacement, and study the link between magnesium insufficiency and AF.
Philips also signed a technology agreement with Dutch Franciscus Gasthuis & Vlietland hospital to develop a future-proof operating suite and intervention center. As part of the deal, PHG will offer its next-generation image-guided therapy platform, Azurion, to the intervention center, further strengthening its position as a leader in image-guided treatments.
Portfolio Strength: Key Catalyst
Philips is making concerted efforts to bolster its portfolio in order to gain further customer momentum.
The company introduced Philips Image Guided Therapy Mobile C-arm System 9000 and Zenition 90 Motorized, enhancing clinicians' productivity with automated workflows like Touch Screen Module and meeting complex vascular needs.
Philips launched an AI-enabled cardiovascular ultrasound platform with FDA 510(k) clearance, boosting its Precision Diagnosis portfolio. The platform combines Philips’ EPIQ CVx and Affiniti CVx ultrasound systems, enhancing cardiac ultrasound analysis speed and reducing echocardiography lab workload.
PHG also unveiled HealthSuite Imaging, an AI-enabled cloud-based Picture Archiving and Communication System, which offers high-speed remote diagnostic reading, integrated reporting and AI-powered workflow orchestration, enhancing operational efficiency and patient care.
A strong portfolio, coupled with an expanding clientele, is expected to continue driving Philips’ financial performance in the upcoming period.
For 2024, Philips expects to deliver 3-5% of comparable sales growth.
The Zacks Consensus Estimate for 2024 revenues is pegged at $19.99 billion, implying year-over-year growth of 1.7%.
The consensus mark for 2024 earnings is pegged at $1.50 per share, indicating an 11.1% rise from the year-ago figure. The figure has remained unchanged in the past 30 days.
Zacks Rank & Stocks to Consider
Currently, Philips carries a Zacks Rank #3 (Hold).
Image: Bigstock
Philips (PHG) Extends Isala Partnership, Boosts Customer Base
Philips (PHG - Free Report) recently announced the renewal of its long-standing partnership with Isala hospital in a bid to enhance healthcare delivery through innovative, cost-effective solutions.
Per the terms, Isala hospital will use Philips' technology to optimize healthcare processes and deliver patient-centered, accessible, affordable, and cost-effective care.
The hospital will also replace medical systems like MRI and CT scanners with Philips' essential imaging systems and support services, ensuring continuous updates and sustainability.
The latest partnership has added strength to Philips’ customer base.
Koninklijke Philips N.V. Price and Consensus
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
Expanding Customer Base
Philips’ shares have gained 26.4% in the year-to-date period, outperforming the industry’s growth of 6.2%. The company is benefiting from a strengthening clientele on the back of its strong portfolio.
Philips entered into a 10-year strategic collaboration with Nicklaus Children's Health System. Nicklaus will use Philips technologies like Ingenia Ambition X MR and EPIQ CVx ultrasound, AI-enabled radiology workflow solutions, and patient experience technologies to improve patient and staff experience, outcomes, and innovation in pediatric care.
Philips expanded its clientele with the Bon Secours Mercy Health (BSMH) partnership. Per the terms, BSMH will utilize Philips’ scalable patient monitoring platform, standardizing data integration for 49 hospitals, reducing costs and enabling reinvestment in innovation.
Moreover, 14 major hospitals across Madrid, Barcelona, Bilbao, Alicante, Madrid, Cadiz, and Navarra are using Philips’ ambulatory cardiac monitoring service to detect post-discharge Atrial Fibrillation (AF), monitor patients for AF after cardiac ablation or heart valve replacement, and study the link between magnesium insufficiency and AF.
Philips also signed a technology agreement with Dutch Franciscus Gasthuis & Vlietland hospital to develop a future-proof operating suite and intervention center. As part of the deal, PHG will offer its next-generation image-guided therapy platform, Azurion, to the intervention center, further strengthening its position as a leader in image-guided treatments.
Portfolio Strength: Key Catalyst
Philips is making concerted efforts to bolster its portfolio in order to gain further customer momentum.
The company introduced Philips Image Guided Therapy Mobile C-arm System 9000 and Zenition 90 Motorized, enhancing clinicians' productivity with automated workflows like Touch Screen Module and meeting complex vascular needs.
Philips launched an AI-enabled cardiovascular ultrasound platform with FDA 510(k) clearance, boosting its Precision Diagnosis portfolio. The platform combines Philips’ EPIQ CVx and Affiniti CVx ultrasound systems, enhancing cardiac ultrasound analysis speed and reducing echocardiography lab workload.
PHG also unveiled HealthSuite Imaging, an AI-enabled cloud-based Picture Archiving and Communication System, which offers high-speed remote diagnostic reading, integrated reporting and AI-powered workflow orchestration, enhancing operational efficiency and patient care.
A strong portfolio, coupled with an expanding clientele, is expected to continue driving Philips’ financial performance in the upcoming period.
For 2024, Philips expects to deliver 3-5% of comparable sales growth.
The Zacks Consensus Estimate for 2024 revenues is pegged at $19.99 billion, implying year-over-year growth of 1.7%.
The consensus mark for 2024 earnings is pegged at $1.50 per share, indicating an 11.1% rise from the year-ago figure. The figure has remained unchanged in the past 30 days.
Zacks Rank & Stocks to Consider
Currently, Philips carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical market sector are Alcon (ALC - Free Report) , Quest Diagnostics (DGX - Free Report) and Eli Lilly (LLY - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alcon shares have gained 36.2% in the year-to-date period. ALC’s long-term earnings growth rate is currently projected at 14.58%.
Quest Diagnostics shares have gained 13% in the year-to-date period. DGX’s long-term earnings growth rate is currently projected at 6.18%.
Eli Lilly shares have rallied 28.2% in the year-to-date period. The long-term earnings growth rate for LLY is currently projected at 32.99%.